Fusion protein · Agonist of IL-2/IL-15 receptor beta-gamma · developed by Altor Bioscience, Llc, An Indirect Wholly-Owned Su
Nogapendekin alfa inbakicept is a fusion protein composed of a mutated IL-15 (IL-15N72D) fused to an IL-15 receptor alpha-Fc domain. It acts as an IL-15 receptor agonist, activating NK cells, CD8+ T cells, and memory T cells through the IL-2/IL-15 receptor.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 24, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07524257 | Phase 3 | NSCLC (Advanced Non-small Cell Lung Cancer) | Withdrawn | IBRX |
| NCT07492875 | Phase 3 | Community-Acquired Pneumonia (CAP) | Withdrawn | IBRX |
| NCT03520686 | Phase 3 | Non Small Cell Lung Cancer | Terminated | IBRX |
| NCT03022825 | Phase 2/3 | Bladder Cancer | Active not recruiting | IBRX |
| NCT07355205 | Phase 1/2 | Non-small Cell Lung Cancer Stage IV | Recruiting | IBRX |
| NCT07492888 | Phase 2 | Acute Respiratory Distress Syndrome | Withdrawn | IBRX |
| NCT07108036 | Phase 2 | Long COVID | Recruiting | IBRX |
| NCT06829823 | Phase 2 | Non-muscle Invasive Bladder Cancer (NMIBC) | Not yet recruiting | IBRX |
| NCT07123727 | Phase 2 | Long COVID | Recruiting | IBRX |
| NCT06239220 | Phase 2 | Head and Neck Cancer | Recruiting | IBRX |
| NCT03228667 | Phase 2 | Non-Small Cell Lung Cancer | Active not recruiting | IBRX |
| NCT03317158 | Phase 1/2 | Urothelial Carcinoma | Active not recruiting | IBRX |
| NCT02782546 | Phase 2 | Acute Myeloid Leukemia | Active not recruiting | IBRX |
| NCT07488884 | Phase 1 | Pancreatic Cancer Resectable | Withdrawn | IBRX |
| NCT05618925 | Phase 1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Recruiting | IBRX |
| NCT04898543 | Phase 1 | Metastatic Solid Tumor | Active not recruiting | IBRX |
| NCT05981131 | N/A | Non Muscle Invasive Bladder Cancer | Active not recruiting | IBRX |
| NCT06956547 | N/A | Lymphopenia | Available | IBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaBladder CancerCervical CancerColorectal CancerGastric CancerHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaMelanomaMerkel Cell CarcinomaMicrosatellite InstabilityMismatch Repair DeficiencyNon-Small Cell Lung CancerRenal Cell CarcinomaSmall Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.
See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBRX catalysts and pipeline →